Therefore, it is possible that GLP-1 analogs, as a treatment for Alzheimer’s disease, produce observable neuroprotective effects on both brain structure and function, thus reducing the decline in participants’ cognitive function. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.